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Abstract
An in-depth knowledge of the host molecules and biological pathways that contribute towards the pathogenesis of
cerebral malaria would help guide the development of novel prognostics and therapeutics. Genome-wide transcriptional
profiling of the brain tissue during experimental cerebral malaria (ECM ) caused by Plasmodium berghei ANKA parasites in
mice, a well established surrogate of human cerebral malaria, has been useful in predicting the functional classes of genes
involved and pathways altered during the course of disease. To further understand the contribution of individual genes to
the pathogenesis of ECM, we examined the biological relevance of three molecules – CD14, galectin-3, and OX40 that were
previously shown to be overexpressed during ECM. We find that CD14 plays a predominant role in the induction of ECM and
regulation of parasite density; deletion of the CD14 gene not only prevented the onset of disease in a majority of
susceptible mice (only 21% of CD14-deficient compared to 80% of wildtype mice developed ECM, p,0.0004) but also had
an ameliorating effect on parasitemia (a 2 fold reduction during the cerebral phase). Furthermore, deletion of the galectin-3
gene in susceptible C57BL/6 mice resulted in partial protection from ECM (47% of galectin-3-deficient versus 93% of
wildtype mice developed ECM, p,0.0073). Subsequent adherence assays suggest that galectin-3 induced pathogenesis of
ECM is not mediated by the recognition and binding of galectin-3 to P. berghei ANKA parasites. A previous study of ECM has
demonstrated that brain infiltrating T cells are strongly activated and are CD44
+CD62L
2 differentiated memory T cells [1].
We find that OX40, a marker of both T cell activation and memory, is selectively upregulated in the brain during ECM and its
distribution among CD4
+ and CD8
+ T cells accumulated in the brain vasculature is approximately equal.
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Introduction
Cerebral malaria (CM) is the most severe consequence of a
Plasmodium falciparum infection and along with severe anemia is a
major pathogenic factor behind the approximately 1 million
deaths per year, mostly in children aged 2–5 years living in sub-
Saharan Africa. In endemic areas, CM has been described as
presence of a set of well-defined clinical features with the primary
characteristics of unarousable coma, exclusion of encephalopa-
thies, and confirmation of P. falciparum infection [2].
A substantial amount of our knowledge regarding the
underlying molecular mechanisms that contribute towards the
pathogenesis of CM comes from studies using the P. berghei ANKA
murine model of experimental cerebral malaria (ECM), a well-
established surrogate of human CM. In this murine model,
depending on the host genetic background, mice can be broadly
categorized as susceptible or resistant to ECM. Although infection
results in eventual death of all mice, the majority of susceptible
mice develop neurological symptoms between days 6–10 post-
infection that closely mimic human CM. In contrast, resistant mice
(as well as a small portion of susceptible mice) do not exhibit
clinical or pathological symptoms of ECM during this 6–10 day
window of infection but instead succumb to hyperparasitemia and
severe anemia between days 15–21 post-infection.
Several decades of experimental evidence suggest that the clinical
manifestations of ECM result from immuno-pathological events that
include: 1) the sequestration of mature form parasites in brain
capillaries (sequestration hypothesis) [3]; 2) overexpression of
inflammatory mediators such as TNF-a (cytokine hypothesis) [4];
and 3)disruption of thebloodbrainbarrier byCD8
+T cellmediated
apoptosis of endothelial cells (permeability hypothesis) [5,6]. Recent
studies performed in gene deficient mice have confirmed that this
complex polygenic trait is influenced by the participation of a
growing number of functionally diverse host factors.
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first recognized when it was reported that athymic nude mice do not
develop symptomsofECM duringaPb-A infection[7].Subsequently,
studies based on depletion of T cell subsets in mice and in CD4- and
CD8-deficient mice established that both CD4
+and CD8
+T cellsare
required for the development of ECM [8,9]. Importantly, CD4
+ T
cells are critical for the induction of ECM, whereas CD8
+ Tc e l l sa r e
critical during the effector phase of ECM [10]. Accumulating
evidence suggests that brain infiltrating T cells during ECM are
strongly activated and differentiated memory cells [1].
Previously, we utilized a host genome-wide approach to identify
specific alterations in transcription levels by microarray of host
genes in mice in the moribund state. After accounting for
confounding factors such as mouse genetic background, parasite
burden, and disease state (e.g., moribund vs. non-moribund and
susceptibility vs. resistance to ECM), we found that more than 200
host genes, based on their transcriptional alterations, were
associated with the pathogenic events occurring during ECM
[11]. Next we wanted to determine which of the transcriptional
altered genes in our dataset were directly involved in the
pathogenesis of ECM. The initial criterion for the selection of
molecules for further studies was based on functional properties
(e.g. cytoadherence, immunological, and inflammatory, etc.) that
may suggest a role in the pathogenesis of ECM. These functional
properties were ascertained based on earlier published studies and
by extensive bioinformatics analyses. Using these criteria, we chose
to examine the biological relevance of three molecules - CD14,
galectin-3, and OX40 in our dataset that we predicted, based on
their function, may play a direct role in the pathogenesis of ECM.
CD14 is a leucine-rich-repeat (LRR) surface protein related to
the extracellular LRR-portion of the TLR proteins. It has two well
characterized functions that may be pertinent to the pathogenesis
of ECM: 1) it is a receptor for lipopolysaccharide of Gram negative
bacteria [12] and recognition of microbial ligands by host CD14
often results in the activation of a potent inflammatory cascade,
including the release of TNF-a and IL-1b. 2) CD14 is a major
receptor involved in the nonphlogistic clearance of cells undergo-
ing apoptosis [13] and its overexpression in the brain may reflect
the well-documented increase in endothelial and neuronal
apoptotic cells during ECM [6,14,15].
Galectin-3 belongs to a large family of animal lectins defined by
an evolutionary conserved carbohydrate-recognition-binding do-
main (CRD), which recognizes b-galactosides. Galectin-3 has a
preference for larger oligosaccharides, such as polyNAc-lactosa-
minoglycan, a polymer of beta (1,3)-linked LacNAc units found on
many extracellular matrix and cell surface molecules [16,17].
Galectin-3 lacks conventional signal peptides and has been
localized to the nucleus and cytoplasm [18,19]. However, it is
also secreted by a non-classical pathway and is found on cell
surfaces as well as the extracellular matrix. A wide array of
functions has previously been assigned to this molecule including
the regulation of inflammation [17,20], apoptosis [21,22],
chemotaxis [23], and cell adhesion [24]. However, given that its
preferred target is predominantly extracellular rather than
intracellular proteins, it is likely to have a role in interacting with
endogenous extracellular glycoproteins or foreign pathogen
associated molecular patterns (PAMPs) [25]. Because of these
observations and previous reports that galectin-3 can significantly
alter the pathogenic course of Trypanosoma cruzi [26], Schistosoma
mansoni [27], Toxoplasma gondii [28], and Leishmania major [29]
protozoan infections, we selected this molecule for further
examination of a functional role during ECM.
CD4
+ and CD8
+ T cells have been shown to be necessary for
the development of ECM [7–9]. Therefore, we also investigated
the role of the costimulatory molecule OX40 during ECM. OX40,
a member of the tumor necrosis factor receptor superfamily [30],
is expressed primarily on activated T cells [31] and has been
shown to play an important role in the generation of memory
[32,33]. We were particularly interested in measuring the
proportion of T cells expressing OX40 because a large portion
of brain infiltrating CD4
+ and CD8
+ T cells have been shown to
be differentiated memory T lymphocytes during ECM [1].
Results
Infection with Pb-A parasites is fatal in 100% of mice. However,
the cause of death may vary from ECM to hyperparasitemia and
severe anemia depending on the host genetic background. In this
study, all in vivo murine experiments were performed on the
C57BL/6 background, where in our hands, 80–100% of wildtype
(WT) mice develop symptoms of ECM.
CD14-KO mice are protected against ECM and protection
is parasitemia dependent
A correlation between elevated levels of soluble CD14 in serum and
complicated P. falciparum malaria in humans has previously been
reported [34]. In addition, overexpression of CD14 transcription in
brain tissue of susceptible mice exhibiting symptoms of ECM has
recently been described by our group [11]. To delineate a biological
role for CD14 in the pathogenesis of ECM, we measured the
susceptibility of CD14-KO mice to ECM. Simultaneously, we also
determined if absence of host CD14 had an influence on the in vivo
growth of intra-erythrocytic paras i t e sw h i c hm a yi nt u r ni n f l u e n c e
susceptibility to ECM. In cumulative data collected from two
independent experiments (n=10 per group for experiment 1 and 9
CD14-KO and 10 WT for experiment 2), we find that following
infection with Pb-A parasites, 16 of 20 (80%) WT mice developed
ECM (Fig. 1A) by day 8. In comparison, only 4 of 19 (21%) CD14-KO
mice developed symptoms of ECM indicating that loss of CD14
confers a highly significant protection from ECM (p,0.0004, Fisher’s
exact test). These results strongly indicate that CD14 plays an
important role in the expression of ECM. Although protection in
CD14-KO mice was highly significant, this protection was incomplete,
suggesting that additional host molecules with functionally redundant
roles may be able to substitute for CD14 in the pathogenesis of ECM.
Surprisingly, we also find that loss of CD14 had an adverse effect
on parasite growth in C57BL/6 mice (p,0.0001, two-way
ANOVA). Among mice that did not develop ECM, between days
6 to 8 post-infection, mean parasite burden was approximately 2-
fold lower in CD14-KO mice compared to WT mice (4.2% vs.
8.3% on day 6) (Fig. 1B). The difference in parasitemia was even
more drastic (3.6-fold lower) between days 9 (4.6% vs. 16.9%) and
13 (12.2% vs. 43.6%), the post-ECM phase. However, among mice
that developed ECM, there was no significant difference in mean
parasitemia between WT (8.16.6% on day 6) and CD14-KO
(8.362.2% on day 6) mice during the cerebral phase (p=0.9185,
Mann2Whitney test) (Fig. 1C). Although it is possible that the dual
roles of CD14 as a mediator of the pathogenesis of ECM and a
positive regulator of parasite density operate independent of each
other, our results suggest that CD14-mediated pathogenesis of
ECM is directly dependent on the level of parasitemia; CD14-KO
mice that were able to overcome resistance to ECM (n=4) had a
parasite burden similar to WT mice.
Deletion of the lgals3 gene results in partial protection
from ECM
We previously reported that transcription of galectin-3 is
induced in brain tissue of susceptible mice that develop ECM
CD14 and Galectin-3 Induce ECM
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galectin-3 was overexpressed by 6.8 fold in moribund mice [11]. In
this study, we quantified the amount of galectin-3 protein in brain
tissue of mice during the cerebral phase in order to establish
whether galectin-3 expression in the brain is a reliable biomarker
of the clinical state of ECM. In an ECL-based, semi-quantitative
western blot assay, galectin-3 protein expression (represented in
average integrated optical densities [IOD] units) was significantly
higher in moribund (9,62061,058) than in non-moribund
(1,6206381), CD8-KO (2,2006265) and normal mice
(9006208). Thus, compared to non-moribund and resistant
CD8-KO mice, moribund mice exhibited a 5.9 and 4.4 fold
increase, respectively in galectin-3 protein expression (Fig. 2).
We next measured the susceptibility of galectin-3-KO mice to
ECM following infection with Pb-A parasites. In a cumulation of
two independent experiments, 14 of 15 (93%) WT mice developed
ECM (Fig. 3A) by day 7 post-infection. In comparison, only 8 of 17
galectin-3-KO mice (47%) developed symptoms of ECM by day 8
post-infection, indicating that loss of galectin-3 conferred signif-
icant (p,0.0073, Fisher’s exact test) protection from ECM. We
also determined parasitemia beginning on day 4 post infection.
Interestingly, in mice that developed ECM, parasitemia was
moderately higher in galectin-3-KO mice compared to WT mice
(p,0.0137, two-way ANOVA) (Fig. 3B). Similarly, among mice
that did not develop ECM, although parasitemia did not differ
greatly between days 4 and 12, we noted that parasitemia was
markedly higher on day 20 in the galectin-3-KO (53.368.29%)
versus WT (36%) group. Because previous studies have demon-
strated an ability of galectin-3 to adhere to T. cruzi, S. mansoni, and
L. major protozoan parasites [26,27,29], we investigated whether
galectin-3 induced pathogenesis of ECM might be mediated by the
binding of galectin-3 to Pb-A parasites. Therefore, we measured
the capacity of galectin-3 to adhere to malaria parasites after
incubation of mouse recombinant galectin-3 with Pb-A schizonts
for 1 h at 37uC. We find that galectin-3 binding to parasites
(Fig. 4B) was not significantly above background levels (Fig. 4A).
We also noticed low levels of galectin-3 binding to mouse
lymphocytes. This binding decreased slightly in the presence of
sucrose, a control disaccharide that is not recognized by galectin-3
(Fig. 4C), and lactose, a competitive disaccharide that has a high
affinity for galectin-3 (Fig. 4D), suggesting that the observed
adherence of galectin-3 to lymphocytes may be nonspecific.
Selective expression of OX40 during experimental
cerebral malaria
OX40 is a costimulatory molecule involved in T cell activation
and generation of memory. OX40 has previously been implicated
in the pathogenesis of several inflammatory diseases such as
multiple sclerosis [35,36], inflammatory bowel disease [37], and
rheumatoid arthritis [38,39]. In our dataset, transcription of
OX40 in the brain was increased by approximately two fold in
moribund mice compared to non-moribund and resistant mice
[11]. We wanted to determine if OX40 protein is preferentially
expressed in the brain during ECM. To accomplish this, we
performed immunohistological studies in brain sections from
C57BL/6 moribund and non-moribund mice. We found that mice
displaying symptoms of ECM strongly expressed OX40 on a
subset of lymphoid cells in the brain (Fig. 5A). In comparison,
tissue sections from non-moribund mice had much fewer cells
expressing OX40 (Fig. 5B) suggesting that expression of OX40 in
the brain during Pb-A infection may correlate with disease
progression.
We next performed flow cytometric analysis to determine the
percentage of T cells accumulated in the brain vasculature that
Figure 1. Deletion of CD14 confers protection against ECM and
has a negative effect on parasite growth in vivo. C57BL/6 WT and
CD14-KO mice were challenged with 10
6 Pb-A parasites and suscepti-
bility to ECM was determined based on symptoms exhibited and ability
of mice to survive beyond day 10 post-infection. A: 16 of 20 (80%) WT
mice versus 4 of 19 (21%) CD14-KO mice succumbed to ECM by day 10
post-challenge. B: CD14-KO mice that did not develop ECM had
approximately 2-fold lower parasite burden between days 6 to 8 and
3.6-fold lower parasite burden between days 9 to 13 post-Pb-A
infection. C: In contrast, WT and CD14-KO mice that developed ECM
had no significant differences in parasite burden at onset of ECM.
doi:10.1371/journal.pone.0006793.g001
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that 19.562.4% of CD3
+ brain lymphocytes expressed OX40.
Because OX40 is expressed on both CD4
+ and CD8
+ T cells and
both subsets are known to play an active role in the pathogenesis of
ECM, we next wanted to examine the distribution of OX40
among T cell subsets. During the symptomatic effector phase of
ECM, we found that 13.68% and 84.34% of CD3
+ brain
lymphocytes were CD4
+CD8
2 and CD4
2CD8
+ T cells, respec-
tively (Fig. 6A). However, although there were comparatively fewer
CD4
+ T cells in the brains of mice with ECM, a majority of these
CD4
+ T cells (74.30%) expressed OX40 (Fig. 6B). Conversely,
although 84.34% of CD3
+ brain lymphocytes were CD8
+ T cells,
only 7.59% of these CD8
+ T cells expressed OX40 (Fig. 6C).
Consequently, although the proportion of CD4
+ and CD8
+ T cell
subsets differed greatly in the brain during the effector phase of
ECM, the absolute number of CD4
+OX40
+ (11846250) and
CD8
+OX40
+ (9766388) T cells remained approximately the same
(Fig. 6D). We also measured the expression of OX40 in the spleen
of mice with ECM and found that similar to the brain, OX40 was
predominantly expressed on CD4
+ T cells; 42.9% of CD4
+ versus
3.9% of CD8
+ splenic T cells expressed OX40 (data not shown).
We also performed flow cytometric analysis of T cell subsets in
infected C57BL/6 non-moribund mice. Results showed that non-
moribund mice had fewer CD4
+OX40
+ (1726138) and
CD8
+OX40
+ (55644) T cells in the brain compared to moribund
mice. This reduction in OX40
+ brain lymphocytes is most likely a
consequence of the significantly fewer CD3
+ lymphocytes
observed in the brain of non-moribund (15926800) compared
to moribund (13,07263881) mice.
Discussion
Based on our microarray dataset, we chose to determine the in-
depth role of three molecules in the pathogenesis of ECM in mice.
First, our results demonstrate that the CD14 molecule plays a key
role as a mediator of the pathogenesis of ECM. In earlier studies,
the presence of elevated levels of soluble CD14 in serum from
patients with complicated P. falciparum malaria has been reported
[34]. Consistent with these findings, induction of CD14 transcrip-
tion in brain tissue of susceptible mice exhibiting symptoms of
ECM has recently been described by our group. In this microarray
study, transcription of ECM was increased by 2.760.1 and
6.260.9 fold during ECM compared to BALB/c resistant and
C57BL/6 non-moribund mice, respectively [11]. Further investi-
gation in mice deficient for the CD14 gene revealed that loss of
CD14 had a dual effect following infection with Pb-A parasites.
First, CD14-deficient mice were highly resistant to ECM (only
21% of CD14-KO versus 80% of WT mice developed ECM,
p,0.0004) (Fig. 1A) and secondly, loss of ECM associated with a
significantly reduced parasite burden throughout the course of Pb-
A infection in CD14-KO mice (Fig. 1B). Curiously, our data
showing that loss of CD14 molecule associated with protection
from ECM is somewhat in conflict with a previous study [40] in
which 100% of mice deficient for the CD14 gene developed fatal
ECM within 6 to 8 days after infection with 10
6 P. berghei ANKA-
parasitized RBCs. The reason behind the inconsistent findings as
reported here and in the earlier study is not clear. However, we
would like to emphasize that while our results are based on two
independent ECM studies that involved a total of 19 CD14-KO
mice, the study by Togbe et al [40] used only 7 CD14-KO mice in
two independent experiments. Although the CD14-KO mice used
in our study and the Togbe et al study were derived from the same
genetic stock [41], it is possible that the CD14-KO strains used in
the two studies differ in a subtle way that needs to be further
examined. One such subtle difference is that the Togbe et al study
utilized CD14-KO mice that were backcrossed at least ten times
on the C57BL/6 genetic background while the CD14-KO mice
used in our study (N7F14N1 mice) were backcrossed eight times.
Differences in the Pb-A parasite lines could also account for the
discrepant results between the two studies. Green fluorescent
protein transgenic parasites derived from the cl15cy1 clone of Pb-A
were used in the Togbe et al study while in this study, we used an
uncloned line of Pb-A parasites that had undergone no genetic
manipulation. Additional studies using a large sample size of mice
will enhance our knowledge of the role of CD14 in ECM.
Nonetheless, we have noted that in agreement with our results,
Togbe et al also find that compared to WT C57BL/6 mice, CD14-
KO mice had a more than two-fold reduction in parasite burden
on day 7 post-Pb-A infection. In their study, parasite burden was
not reported for the entire course of Pb-A infection.
CD14 exerts it pro-inflammatory action by acting as an
accessory molecule for TLRs [42,43]. Recent studies have shown
that malaria GPI and hemozoin are ligands for TLR2 and TLR9,
respectively [44,45]. However, studies investigating the role of
TLR signaling pathways in the pathogenesis of ECM are
conflicting. In a study conducted by Coban et al, TLR2
2/2 and
TLR9
2/2 mice, but not TLR4
2/2, TLR5
2/2, and TLR7
2/2
mice, were significantly protected from ECM [46]. Griffith et al
demonstrated that TLR9
2/2 mice, but not TLR2
2/2 and
TLR4
2/2 mice, were partially protected from ECM [47]. In
contrast, Togbe et al. found that TLR2
2/2 and TLR9
2/2 mice, as
well as TLR3
2/2, TLR4
2/2, TLR6
2/2, and TLR7
2/2 mice,
were as sensitive to ECM as WT mice [40]. In agreement with
Togbe et al, a study employing triple knockout mice found that the
survival rates of TLR2/4/9
2/2 mice were comparable to WT
mice after Pb-A infection [48]. While our study does not
differentiate between the TLR-dependent and TLR-independent
roles of CD14, on the whole the above considerations are not
Figure 2. Induction of galectin-3 during experimental cerebral malaria. Expression of galectin-3 was measured in brain tissue samples in
individual moribund (n=5), non-moribund (n=5), CD8-KO (=3), and normal (non-infected, n=3) C57BL/6 mice by ECL-based western blot analysis.
Expression levels were determined based on the intensity of protein bands using Meta1 Morph 6.1 software and are represented as average
integrated optical densities (IOD) units. The IOD units shown are values61000. Details of antibodies and western blot reagents used can be found in
the Materials and Methods.
doi:10.1371/journal.pone.0006793.g002
CD14 and Galectin-3 Induce ECM
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6793inconsistent with CD14 acting via the TLR signaling pathways in
ECM.
An unexpected result of this study was that loss of CD14 had an
adverse effect on parasite growth in C57BL/6 mice. Mean parasite
burden was approximately 2-fold lower (days 6 to 8 post-infection)
and 3.6-fold lower (days 9 to 13 post-infection) in CD14-KO mice
compared to WT mice (Fig. 1B). Importantly, resistance of CD14-
KO mice to ECM was parasitemia dependent; the few CD14-KO
mice that developed ECM had a parasite burden comparable to
WT mice (Fig. 1C). Interestingly, this is not the first study to report
the ability of CD14-deficient mice to control a pathogen burden
more efficiently than WT mice. In a study conducted by Haziot et
al, CD14-deficient mice were not only resistant to a lethal
challenge (5610
6 cfu) of Escherichia coli 0111:B4, but also had a 27-
fold lower level of bacteremia in the blood [49]. This increased
clearance of E. coli by CD14-deficient mice was attributed to a
rapid infiltration of neutrophils (PMNs) in the peritoneal cavity
that was significantly delayed in normal mice [50]. It is important
to note that neutrophils have been shown to phagocytose and kill
malaria parasites in vitro [51–53]. Nonetheless, further studies are
needed to determine the mechanism of CD14 dependent
regulation of Pb-A parasite density. Regardless of the mechanism,
a therapeutic agent that targets CD14 could potentially be useful
in preventing CM while simultaneously lowering parasite burden.
Importantly, administration of human recombinant soluble CD14
(rsCD14) that might compete with CD14 receptor significantly
protected mice from LPS-induced mortality [54].
We have also demonstrated that galectin-3 protein is overex-
pressed in mice exhibiting symptoms of ECM (Fig. 2) and deletion
of the galectin-3 gene confers partial but significant (p,0.0073)
protection from ECM in C57BL/6 mice challenged with Pb-A
(Fig. 3A). To our knowledge, this is the first study to address the
role of galectin-3 in the pathogenesis of malaria. In previous
studies, important and diverse roles have been assigned to galectin-
3 during other protozoan parasite infections [26,27,28]. Interest-
ingly, in a study evaluating the role of galectin-3 in leishmaniasis,
galectin-3 recognized lipophosphoglycan (LPG) of L. major but not
L. donovani and this species-specific recognition of the polygalactose
epitope of L. major LPG resulted in cleavage of galectin-3 to a
truncated form that is incapable of oligomerization, a prerequisite
for the immunomodulatory activities of galectin-3 [29]. The
authors proposed that truncation of galectin-3 during L. major but
not L. donovani infection may account for differences in
pathogenesis between the two species. A similar type of
mechanism related to the processing of galectin-3 that is triggered
by only a few Plasmodium species might be a reason why not all
malaria parasites cause the pathogenesis of CM in their respective
hosts.
The above mentioned studies and our data provide evidence
that galectin-3 can significantly alter the pathogenic course of a
parasitic disease. In a majority of these infections, the role of
galectin-3 appears to depend on direct interaction with the
parasite. However our studies did not find any significant
adherence of galectin-3 to schizont stage parasites (Fig. 4B) above
background levels (Fig. 4A). We speculate that rather than binding
parasite moieties, the role of galectin-3 in ECM might result from
its binding endogenous oligosaccharides on matrix proteins.
Galectin-3 is predominantly expressed in macrophages [23] and
might be released upon lysis of brain-infiltrating macrophages. It
has been observed that in galectin-3-KO mice, alternative
macrophage activation induced by extracellular galectin-3 via
IL-4/IL-13 is repressed [55], suggesting that this pathway might
be involved in the role of ECM. In light of the results obtained in
the leishmaniasis study, we systemically surveyed the galectin-3
Figure 3. Galectin-3 deficient mice are partially protected
against experimental cerebral malaria and developed higher
peripheral parasitemia. A: Fourteen of 15 (93%) WT mice versus 8 of
17 (47%) galectin-3-KO mice succumbed to ECM by day 8 post-
infection. Data shown is cumulated from two independent experiments.
B: In galectin-3-KO (n=5) and WT (n=9) mice that developed ECM,
galectin-3-KO mice had moderately higher parasitemia than WT mice
(p,0.0137, two-way ANOVA). C: Among mice that did not develop
ECM, although parasitemia did not differ markedly between days 4 and
12, parasitemia was higher on day 20 in the galectin-3-KO (53.368.29%,
n=4) versus WT (36%, n=1) group.
doi:10.1371/journal.pone.0006793.g003
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hapmap.org). We discovered that this molecule contains one
protein-coding SNP (rs4652, A/C) that shows a dramatic
difference between sub-Saharan African and non-African popu-
lations (96% of chromosomes from the former show the C allele).
This particular SNP maps to the N-terminal low-complexity
region, which is unique to galectin-3 among members of the
galectin family and is required for high avidity binding to
multivalent glycoconjugates [56]. This low complexity segment is
required for multimerization of galectin-3 [57] and is predicted to
adopt a potentially collagen-like structure as a consequence of its
repeating pattern of glycines and prolines. Given that the A/C
SNP produces a P/T substitution, it could affect the multi-
merization of galectin-3. Hence, the difference between the sub-
Saharan African and non-African populations at this protein
position might be a reflection of selection driven by malaria which
Figure 4. Pb-A parasites collected from whole blood at approximately 10% parasitemia were cultured overnight to obtain schizont
stage parasites. Parasites were then incubated with A: no galectin-3 B: galectin-3 C: galectin-3 and sucrose and D: galectin-3 and lactose and
subsequently stained with a goat antibody specific for galectin-3 and a fluorescent donkey antibody specific for goat IgG. Right panels show galectin-
3 adherence to mouse lymphocytes. Images were collected on an epifluorescence microscope.
doi:10.1371/journal.pone.0006793.g004
Figure 5. Expression of OX40 in the brain of mice with experimental cerebral malaria. Brain sections from A: moribund and B: non-
moribund Pb-A infected mice were stained with a goat antibody specific for mouse OX40 and visualized at 406magnification. Immunostaining
demonstrated strong but highly specific staining of a subset of lymphoid cells within and adjacent to blood vessels in the brains of moribund mice
(A) but much fewer positive cells were observed in non-moribund (B) mice.
doi:10.1371/journal.pone.0006793.g005
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protection from the lgals3 gene deletion, it might be useful to
further investigate its role as a factor in CM pathogenesis.
We next chose to examine the costimulatory molecule OX40, a
marker of both T cell activation and the generation of memory,
during ECM. Histological examination of brain sections revealed
that mice displaying symptoms of ECM strongly expressed OX40
on a subset of accumulating lymphoid cells in and adjacent to
blood vessels in the brain (Fig. 5A). OX40 was expressed on
comparatively fewer cells in brain tissue of non-moribund mice
(Fig. 5B) suggesting that expression of OX40 in the brain may
correlate with disease progression. Although OX40 is more
commonly expressed on the CD4
+ subset of T cells, expression
has also been observed on CD8
+ T cells that are strongly activated
[58,59]. We measured expression of OX40 on T cell subsets in the
brain by flow cytometry in order to determine whether OX40 is
expressed on CD4
+ or CD8
+ T lymphocytes. In mice exhibiting
symptoms of ECM, 13.68% and 84.34% of CD3
+ brain
lymphocytes were CD4
+ and CD8
+ T cells, respectively (Fig. 6A).
However, we found that OX40 was expressed in the majority
(74.30%) of CD4
+ T cells (Fig. 6B). In contrast, only 7.59% of
CD8
+ T cells co-expressed OX40 (Fig. 6C), but due to the greater
number of CD8
+ T cells in the brain, the absolute numbers of
OX40
+CD4
+ and OX40
+CD8
+ T cells were similar.
While it is difficult to assess the pathogenic nature of CD4
+ T
cells due to their early role in infection, the symptomatic effector
phase of ECM is believed to be precipitated by perforin-mediated
apoptosis of brain endothelial cells by pathogenic CD8
+ T cells
[6]. However, it is not known whether these pathogenic CD8
+ T
cells are a heterogeneous population with multiple phenotypes or a
small homogeneous population such as the OX40
+ subset of CD8
+
T cells accumulated in the brain vasculature characterized in this
study. Future studies performed in mice deficient for OX40 will
need to be performed to determine whether OX40 is necessary for
the pathogenesis of ECM. Furthermore, kinetic analysis by in vivo
depletion of OX40 during different stages of Pb-A infection may be
useful in determining which subset of OX40
+ T cells could
potentially be involved in disease.
We believe that by utilizing a combination of approaches
including mining the dataset of transcriptionally altered genes that
are specifically related to the pathogenesis of ECM and further
investigations in gene knockout mice and immunohistology
Figure 6. OX40 expression on T cell subsets present in the brain of moribund mice. Total brain leukocytes (sequestered and
nonsequestered) were stained with fluorescent-labeled antibodies against TCRb, CD4, CD8, and OX40. The proportion of A: CD4
+ and CD8
+ B:
OX40
+CD4
+ and C: OX40
+ CD8
+ T cells was determined by flow cytometry. D: Although OX40 is preferentially expressed on CD4
+ T cells, due to the
comparatively higher number of CD8
+ T cells in the brain, the absolute number of OX40
+CD4
+ and OX40
+CD8
+ T cells accumulated in the brain
vasculature is approximately the same.
doi:10.1371/journal.pone.0006793.g006
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galectin-3 and OX40 that may play a critical role in the
pathogenesis of ECM. Further in depth studies in mice and
comparative investigations of young children undergoing clinical
symptoms of CM or experiencing asymptomatic malaria during P.
falciparum infections will be required to firmly establish the role of
these molecules in CM.
Materials and Methods
Mice and parasite infections
Six to eight week old female wild type (WT), CD14-KO
(CD14
2/2), galectin-3-KO (gal3
2/2), and CD8-KO (CD8
2/2)
mice on the C57BL/6 background were purchased from The
Jackson Laboratory (Bar Harbor, ME). CD14-KO and galectin-3-
KO mice were incipient congenic mice backcrossed on the
C57BL/6 genetic background eight and six generations, respec-
tively. All mice in these studies were maintained at a National
Institute of Allergy and Infectious Diseases or Food and Drug
Administration animal care facility and treated in accordance and
guidelines of the Animal Care and Use Committee.
P. berghei ANKA (Pb-A) parasites (an uncloned parasite line) were
stored as frozen stabilities in liquid nitrogen at the Laboratory of
Malaria and Vector Research, NIAID. Frozen stabilities were injected
in donor mice that were compatible with the genetic background of
the experimental mice. Subsequently, parasite infection was induced
by intraperitoneal injection of 10
6 Pb-A parasites and mice were
monitored for clinical symptoms of ECM (hemi or paraplegia,
deviation of the head, tendency to roll over upon stimulation, ataxia,
and convulsions) beginning on day 3 post-infection. In most instances,
parasitemia (parasitized RBCs/total RBCs6100) was enumerated by
examining Giemsa-stained thin blood films.
Statistical analysis
The Fisher’s exact test was used to determine differences in
survival between WT and CD14-KO and galectin-3-KO mice.
Differences in parasitemia were analyzed using two-way ANOVA
or the Mann2Whitney test.
Western blot analysis
To determine whether galectin-3 protein expression is associ-
ated with the ECM disease state, expression of galectin-3 protein
was measured in whole brain tissue of moribund and non-
moribund (infected C57BL/6), resistant (infected C57BL/6 CD8-
KO), and normal (uninfected C57BL/6) mice. Brain samples were
taken between days 6 and 10 post-infection. Protein samples from
brain tissue were prepared as a 10% brain homogenate, and tissue
specific galectin-3 protein was detected using antibody specific for
human recombinant galectin-3 (Abcam Inc, Cambridge, MA) and
a commercially obtained chemiluminescence-linked western blot
kit (Western Light Tropix, Bedford, MA). Protein samples were
subjected to electrophoresis on a 4-20% Tris-Glycine PAGE gel
and then transferred onto a PVDF membrane. Following
incubations with the primary and secondary antibodies, protein
bands were visualized with ECL detection reagents, and the
integrated optical densities (IOD) for each lane were measured
using Meta Morph 6.1 Software.
Immunohistological studies
Tissue sections were prepared from the brains of moribund and
non-moribund mice infected with Pb-A for immunohistological
staining of OX40. Brain samples were isolated from mice on day 6
post-infection. Tissue sections were fixed in formalin and then
stained with a goat polyclonal antibody specific for recombinant
mouse OX40/Tnfrsf4 (R&D Systems, Minneapolis, MN). A rabbit
anti-goat antibody (Vector Laboratories, Burlingame, CA) was
used for the next detection step by following the manufacture’s
instructions. Hematoxylin was used as the counterstain. Stained
sections were examined by light microscopy.
Binding of Pb-A parasites to galectin-3
We investigated whether Pb-A infected red cells (IRBC) were able
to bind directly to galectin-3. To accomplish this, whole blood was
collected from mice infected with Pb-A at approximately 10%
parasitemia. Parasites were cultured overnight in RPMI with 20%
fetal calf serum to obtain schizont stage parasites. IRBC were then
fixed in suspension, washed, and resuspended in PBS-0.1% BSA and
fixed IRBC were treated with the following combinations: recombi-
nant mouse galectin-3 (8 mg/ml), recombinant mouse galectin-3
(8 mg/ml) and lactose (20 mM), recombinant mouse galectin-3 and
sucrose (20 mM), lactose (20 mM) alone, or sucrose (20 mM) alone.
Samples were incubated for 1 h at 37uC, washed with PBS-0.1%
BSA, fixed, and then resuspended in PBS-3% BSA. To detect the
b i n d i n go fg a l e c t i n - 3t oI R B C ,s a m p l e sw e r el a b e l e dw i t hag o a ta n t i -
galectin-3 antibody followed by a fluorescent donkey anti-goat IgG.
Images were collected on an epifluorescence microscope.
Single Nucleotide Polymorphism (SNP) analysis of human
galectin-3
To identify potentially relevant SNPs in the genes in this study,
we surveyed the NCBI SNP database using the gene ids for the
respective genes. All SNPs were collated and checked for
significant differences between the 4 principle populations sampled
in HAPMAP. The SNPS showing significant population-wise
differences were then examined for evidence of changing the
coding sequence of the protein or lying next to known
transcription regulatory sites. The former set was also assessed
for positive selection using data from Wang et al [60].
Flow cytometry
We performed flow cytometry to determine the percentage of
CD3
+,CD 4
+,CD 8
+lymphocytes and OX40expressing lymphocytes
in whole brain leukocyte and splenocyte populations taken from mice
undergoing clinical symptoms of ECM on day 6 post-infection.
Preparation of whole brain leukocytes from unperfused brain tissue
was adapted with modifications from a method previously described
[61]. Briefly, single cell suspensions of brain tissue were prepared by
treatment with DNase-I (28 IU/ml; Sigma- Aldrich) and collagenase
(0.5 mg/ml; Sigma- Aldrich) enzymes for 1 hr at 37uCu n d e r
frequent agitation and trituration. Purification of leukocyte popula-
tions was accomplished by centrifugation at 16006g for 20 min on
30% percoll (Sigma-Aldrich) and the gradient layer containing
leukocytes was carefully removed. Splenocytes were prepared by
using a previously described procedure [62].
Single cell suspensions of brain leukocytes and splenocytes were
blocked with anti-CD16-CD32 (BD Biosciences), stained with
FITC-anti-TCRb, APC-anti-CD4, PerCP-anti-CD8, and PE-anti-
OX40 (purchased from either BD Biosciences or eBiosciences) in
PBS containing 2% fetal calf serum for 30 minutes at 4uC, washed
three times, and then analysed on a FACSCalibur flow cytometer
using CellQuest (BD Biosciences) and Flowjo (Treestar) software.
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